The day Medicare officials began discussing whether to set new coverage limits on a costly new prostate-cancer treatment, the official in charge emailed three colleagues to put a “close hold” on the process. That meant: Keep quiet until an announcement later that month.. Yet by the end of that same day, June 7, 2010, shares of the company that made the treatment, Dendreon Corp., had plunged 10%. Before long, federal investigators took notice.